✦ LIBER ✦

Immunotherapy of metastatic melanoma with interferon-α and interleukin-2: Pattern of progression in responders and patients with stable disease with or without resection of residual lesions

✍ Scribed by Keilholz, U; Scheibenbogen, C; Stoelben, E; Saeger, H.D; Hunstein, W

Book ID: 122051921
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 477 KB
Volume: 30
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(94)90122-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final report of a phase II study of inte

Final report of a phase II study of interleukin 2 and interferon α in patients with metastatic melanoma

✍ Kruit, WHJ; Goey, SH; Calabresi, F; Lindemann, A; Stahel, RA; Poliwoda, H; Oster 📂 Article 📅 1995 🏛 Nature Publishing Group 🌐 English ⚖ 507 KB

A Phase II study of “decrescendo” interl

A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy

✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH

Prognostic factors for survival and fact

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin

✍ U. Keilholz; P. Martus; C.J.A. Punt; W. Kruit; G. Mooser; D. Schadendorf; D. Lié 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Randomized trial of treatment with cispl

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-α-2a in patients with metastatic melanoma : A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study

✍ Thierry Dorval; Sylvie Négrier; Christine Chevreau; Marie-Françoise Avril; Danie 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

## Background: The objective of the current study was to evaluate the response rate, survival, and toxicity of treatment with cisplatin and high dose intravenous continuous infusion interleukin-2 (il-2) with or without interferon-alpha-2a (ifn) in patients with metastatic melanoma. ## Methods: On

Prediction of response to combined immun

Prediction of response to combined immunotherapy with interferon-α and low-dose interleukin-2 in metastatic renal cell carcinoma: Expression patterns of potential molecular markers in radical nephrectomy specimens

✍ Hideaki Miyake; Iori Sakai; Mototsugu Muramaki; Toshifumi Kurahashi; Atsushi Tak 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

A randomized trial of pegylated-interfer

A randomized trial of pegylated-interferon-α2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin

✍ A. CIANCIO; A. PICCIOTTO; C. GIORDANINO; A. SMEDILE; M. TABONE; A. MANCA; G. MAR 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB